登录 查看组织和合同定价。
选择规格
变更视图
关于此项目
经验公式(希尔记法):
C15H29N3O5
化学文摘社编号:
分子量:
331.41
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
Assay:
≥98% (NMR)
Form:
solid
Storage condition:
OK to freeze, protect from light
Quality Segment
assay
≥98% (NMR)
form
solid
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze, protect from light
color
white
solubility
DMSO: 15 mg/mL
shipped in
ambient
storage temp.
2-8°C
SMILES string
N(O)C(=O)[C@@H](O)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)(C)C)C(=O)NC
InChI
1S/C15H29N3O5/c1-8(2)7-9(10(19)13(21)18-23)12(20)17-11(14(22)16-6)15(3,4)5/h8-11,19,23H,7H2,1-6H3,(H,16,22)(H,17,20)(H,18,21)/t9-,10+,11-/m1/s1
InChI key
OCSMOTCMPXTDND-OUAUKWLOSA-N
General description
An orally active peptidyl hydroxamate-based broad-spectrum MMP inhibitor (IC50 in nM = 5, 6, 200, 20, 2, 1.8 and 3.8 for MMP-1, -2, -3, -7, -8, -14 and TACE, respectively) that targets both the substrate binding site and the active-site Zn2+. Marimastate is widely used in studying the involvement of MMPs in various cellular and pathological processes both in vitro and in vivo.
Packaging
Packaged under inert gas
Preparation Note
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
Other Notes
Hansen, H.P., et al. 2002. Int. J. Cancer98, 210.
Tsuji, F., et al. 2002. Cytokine17, 294.
Barlaam, B., et al. 1999. J. Med. Chem.42, 4890.
Whittaker, M., et al. 1999. Chem. Rev.99, 2735.
Rasmussen, H.S., and McCann, P.P. 1997. Pharmacol. Ther.75, 69.
Tsuji, F., et al. 2002. Cytokine17, 294.
Barlaam, B., et al. 1999. J. Med. Chem.42, 4890.
Whittaker, M., et al. 1999. Chem. Rev.99, 2735.
Rasmussen, H.S., and McCann, P.P. 1997. Pharmacol. Ther.75, 69.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Toxicity: Standard Handling (A)
Still not finding the right product?
Explore all of our products under Marimastat
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable